Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials
Table 3
Proportion of subjects in the multidose study with a clinically meaningful increase in hemoglobin anytime between baseline and the end of study or time of intervention.
SMC subgroup
FCM
Venofer or Ferrlecit
Oral iron
Other treatment
(%)
187 (64)
59 (57)
68 (45)
22 (52)
Difference from FCM 95% CI
0.07 (−0.05, 0.18)
0.19 (0.09, 0.29)
0.11 (−0.06, 0.29)
/ (%)
IDA Etiology
CKD
15/34 (44)
8/16 (50)
2/11 (18)
1/4 (25)
Heavy uterine bleeding
55/71 (78)
16/25 (64)
25/52 (48)
8/11 (73)
IBD/GI related
41/61 (67)
19/25 (76)
4/15 (27)
7/15 (47)
Postpartum
16/24 (67)
0
8/18 (44)
1/1 (100)
Other/Unknown
60/103 (58)
16/37 (43)
29/56 (52)
5/11 (45)
FCM: ferric carboxymaltose; IDA: iron deficiency anemia; SMC: standard medical care.
